Did You Invest in Gilead Sciences?
OAKLAND, Calif.–(BUSINESS WIRE[1])–The U.S. Government has filed a lawsuit accusing Gilead Sciences of violating patents owned by the U.S. Department of Health and Human Services related to Truvada, Gilead’s HIV prevention drug. Gibbs Law Group has launched a Gilead Sciences Investor Lawsuit investigation[2] on behalf of those who invested in Gilead Sciences (NASDAQ: GILD).
To speak with an attorney regarding this lawsuit investigation, click here[3] or call (888) 410-2925.
On November 6, 2019, the U.S. Department of Health and Human Services filed a lawsuit against Gilead Sciences, accusing the company of infringing on government patents on Truvada, and the concept of “PrEP,” or pre-exposure prophylaxis, which can prevent H.I.V. with a daily pill.
The lawsuit specifically alleges that CDC researchers began studying the preventive use of HIV treatment drugs — like tenofovir, or TDF, and emtricitabine, FTC, the two compounds in a Truvada tablet — as early as 1998, before Gilead sought a patent.
In a statement about the patent lawsuit, Alex Azar II, the secretary of the Department of Health and Human Services stated:
“Gilead must respect the U.S. patent system, the groundbreaking work by researchers with the Centers for Disease Control and Prevention, and the substantial taxpayer contributions to the development of these drugs.”
What Should Gilead Sciences Investors Do?
If you invested in Gilead Sciences, you may have legal claims. Visit our website[4] or contact our securities team directly at (888) 410-2925 to discuss your possible legal options. Our investigation concerns whether Gilead Sciences and certain of its officers and/or directors have violated federal securities laws.
About Gibbs Law Group
Gibbs Law Group represents individual and institutional investors throughout the country in securities litigation[5] to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Top Class Action Attorneys Under 40,” “Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys Under 40.”
This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
References
- ^ BUSINESS WIRE (www.businesswire.com)
- ^ Gilead Sciences Investor Lawsuit investigation (cts.businesswire.com)
- ^ click here (cts.businesswire.com)
- ^ website (cts.businesswire.com)
- ^ securities litigation (cts.businesswire.com)
Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.